CClinicalTrials.gg
Active, not recruitingNCT06859970EASE HF2Updated May 27, 2026

An Early Feasibility Study Evaluation of an Implant Free Interatrial Shunt to Improve Heart Failure

An interventional study of PAS-C System in Heart Failure, Heart Failure NYHA Class III and Heart Failure With Reduced Ejection Fraction, sponsored by InterShunt Technologies, Inc.. Active, not recruiting at 6 sites in United States. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by InterShunt Technologies, Inc. · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as active, not recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
40 Years to 85 Years
Sex
All
01

Study summary

The purpose of this early feasibility study is to evaluate the safety and feasibility of the device for percutaneous shunting of the interatrial septum and improvement of heart failure related symptoms. The primary goal is to determine if the device is safe to use. The findings from this study may be used to refine the intended patient population, the design of the device, or develop a subsequent randomized study.

Read the detailed description

This is a prospective, multicenter, single-arm early feasibility study (EFS) to evaluate the safety of the InterShunt PAS-C System in subjects with heart failure, and the feasibility of PAS-C to improve heart failure related symptoms. The device is used to create an interatrial shunt by removing septal tissue to reduce left atrial pressure. There is no permanent implant. Enrollment will include 20 subjects with documented heart failure who may benefit from the reduction of left atrial pressure. The primary objective of this study is to characterize the safety of using the PAS-C System by evaluating the proportion of subjects who experience a major adverse cardiac or cerebrovascular event or systemic embolization through one month after the procedure. The findings from this study will be used to develop a subsequent pivotal study.

02

Conditions studied

  • Heart Failure
  • Heart Failure NYHA Class III
  • Heart Failure With Reduced Ejection Fraction
  • Ambulatory Heart Failure, NYHA Class IV

Browse trials for

03

In context

Heart Failure

5,701 studies on the registry are indexed under Heart Failure; 1,220 are open to participants now.

This study's planned enrollment of 20 is below the median of 72 across 3,736 interventional studies indexed under Heart Failure.

Browse Heart Failure studies →

Lead sponsor

InterShunt Technologies, Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • NYHA Class II at screening with a prior history of greater than NYHA Class II, OR NYHA Class III at screening, OR ambulatory Class IV at screening: with documented medical history of heart failure for at least 6 months prior to the screening visit.
  • At least one hospitalization for heart failure OR treatment with IV diuretics for heart failure OR elevated BNP in the prior 12 months.
  • Receiving maximally tolerated guideline directed medical therapy for Heart Failure management.
  • LVEF ≥ 20% and ≤ 40% according to baseline echocardiography.
  • Resting right heart catheterization demonstrates elevated PCWP compared to right atrial pressure.

Exclusion criteria

Exclusion Criteria:

  • Any of the following within the prior 6 months: Stroke, thromboembolism, severe or advanced heart failure such as Stage D heart failure, non-ambulatory NYHA Class IV, cardiac index less than 1.8 L/min/m2, LVEDD > 8 cm, or received inotropic therapy for LVEF less than 20%.
  • Any of the following within the prior 3 months: Myocardial infarction percutaneous cardiac intervention, CABG, on cardiac transplant list, cardiac resynchronization therapy implant, AICD implant, or indicated for coronary revascularization at the time of enrollment.
  • Transseptal procedure or percutaneous cardiac intervention planned within the next 6 months.
  • Chronic pulmonary disease requiring continuous home oxygen or hospitalization within the prior 12 months for pulmonary disease.
  • Patent foramen ovale (PFO) device or atrial septal defect (ASD) device.
  • BMI > 40.
  • Anatomic anomaly that precludes creation of interatrial shunt.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    PAS-C System

    The PAS-C System is a catheter designed to remove a small section of septal tissue in the interatrial septum to treat heart failure patients without the need for a permanent implant.

    Device: PAS-C System

Interventions

  • DevicePAS-C System

    All patients will undergo catheterization with the PAS-C System to create an interatrial shunt to reduce left atrial pressure in the heart.

06

What researchers measure

Primary outcomes

  1. Measure of major safety events in the periprocedural timeframe

    Proportion of subjects who experience a major adverse cardiac or cerebrovascular event or systemic embolization

    Time frame: Through one month post procedure

07

Study locations

6 sites
  • St. Bernard's Healthcare
    Jonesboro, Arkansas 72401, United States
  • Los Robles Health System
    Thousand Oaks, California 91360, United States
  • Ascension St. Vincent Hospital
    Indianapolis, Indiana 46260, United States
  • Christ Hospital
    Cincinnati, Ohio 45219, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • Methodist Healthcare
    San Antonio, Texas 78229, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06859970
Lead sponsor
InterShunt Technologies, Inc.
Responsible party
Sponsor
First posted
Mar 5, 2025
Start date
May 15, 2025
Primary completion
Jun 2026 (estimated)
Completion
Sep 2031 (estimated)
Last update
May 27, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion